The main purpose of this study is to understand how safe this combination treatment is by monitoring serious side effects that may occur during therapy. The treatment involves receiving the medications through intravenous infusion. The study will track how patients respond to the treatment and measure both the time until the cancer might progress and overall survival.

The study will include adult patients who have measurable cancer that can be seen on imaging scans and who have not received previous systemic therapy for their recurrent or metastatic disease. Patients must have confirmation of their Epstein-Barr virus status and be in relatively good physical condition to participate.

Participants in this study will undergo PET imaging before and after receiving either induction chemotherapy (medication given to reduce tumor size before main treatment) or chemoradiotherapy (CRT, a combination of chemotherapy and radiation therapy). The imaging will help researchers visualize and measure how the tumor takes up the special tracer substance, which could provide important information about the tumor’s characteristics and potentially help guide future treatment decisions.

The study will test how well Nivolumab works in treating this type of cancer. The medication is given as a solution through an intravenous infusion (directly into a vein). Each patient may receive treatment for up to 6 months, with regular doses of the medication.

During the study, patients will have their condition monitored through various medical examinations, including MRI scans (a type of detailed imaging that uses magnetic fields to create pictures of the inside of the body). The study will track how the cancer responds to the treatment, how long patients live without their disease getting worse, and what side effects may occur from the treatment.

The purpose of the study is to see if this combination of medications can increase the number of patients who have a complete response, meaning no signs of cancer, as seen on imaging tests like MRI and PET-CT. This could potentially allow for a reduction in the amount of radiation therapy needed for children, adolescents, and young adults up to 25 years old with cancer that has not spread beyond the local area.

Participants in the study will receive the medications intravenously, which means they are given through a vein. The study will monitor the complete remission rate, which is the percentage of patients who show no signs of cancer after the treatment. It will also look at other outcomes like event-free survival, overall survival, and the safety and tolerability of the treatment. The study is expected to continue until 2028, with the goal of improving treatment outcomes for patients with this type of cancer.

The purpose of the study is to see if the combination of pembrolizumab and olaparib can improve the response rate in patients compared to historical data where only immunotherapy was used. Participants in the study will receive these treatments over a period of up to 36 months. During this time, they will have regular check-ups and assessments to monitor their health and the cancer’s response to the treatment. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual drugs.

The study will also look at how long patients live without the cancer getting worse, known as progression-free survival, and overall survival, which is the time from the start of treatment until death from any cause. Additionally, the study will assess any side effects experienced by participants and changes in their quality of life using a specific questionnaire designed for head and neck cancer patients. The trial aims to provide valuable information that could lead to better treatment options for people with recurrent or metastatic nasopharyngeal cancer.